The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Fifteen-year-old Isabella Harris has a lot going for her. She’s a talented dancer and a dedicated student, but right now ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Key Takeaways An already approved drug might help kids with a rare bone cancerPazopanib extended survival in a small group of ...

Abstract: Bone cancer represent a diagnosis challenge since this form of cancer appears rarely in patient populations. Traditional convolutional neural networks known as CNNs are frequently used for ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...